Dsp Healthcare Fund Datagrid
Category Pharma Fund
BMSMONEY Rank -
Rating
Growth Option 13-03-2026
NAV ₹36.46(R) -1.26% ₹40.58(D) -1.25%
Returns 1Y 3Y 5Y 7Y 10Y
Lumpsum Regular 0.81% 20.93% 13.87% 19.93% -%
Direct 2.15% 22.56% 15.43% 21.69% -%
Nifty Pharma TRI 12.8% 26.24% 14.52% 14.92% 7.65%
SIP (XIRR) Regular -9.43% 6.06% 11.57% 16.49% -%
Direct -8.2% 7.58% 13.14% 18.22% -%
Ratio Sharpe Ratio Sortino Ratio Sterling Ratio Jensen's Alpha Treynor Ratio
1.08 0.59 0.96 0.33% -0.47
Risk STD. Dev VaR 1Y95% Max DD Beta Semi Devi.
14.57% -17.66% -13.27% 0.8 9.99%
Fund AUM As on: 30/12/2025 3140 Cr
Top Pharma Fund
Fund Name Rank Rating
Mirae Asset Healthcare Fund -

NAV Date: 13-03-2026

Scheme Name NAV Rupee Change Percent Change
DSP Healthcare Fund - Regular Plan - IDCW 21.12
-0.2700
-1.2600%
DSP Healthcare Fund - Direct Plan - IDCW 23.47
-0.3000
-1.2500%
DSP Healthcare Fund - Regular Plan - Growth 36.46
-0.4600
-1.2600%
DSP Healthcare Fund - Direct Plan - Growth 40.58
-0.5100
-1.2500%

Review Date: 13-03-2026

Beginning of Analysis

The Dsp Healthcare Fund has shown a very good past performence in Pharma Fund. The Dsp Healthcare Fund has a Jensen Alpha of 0.33% which is lower than the category average of 1.56%, showing poor performance. The Dsp Healthcare Fund has a Sharpe Ratio of 1.08 which is lower than the category average of 1.19, showing poor performance.
The past performance of the {fund_name_eng} may or may not be sustained in the future. The review is not investment advice nor is it a recommendation to buy or sell funds.
Pharma Mutual Funds

Dsp Healthcare Fund Return Analysis

The Dsp Healthcare Fund has delivered a mixed performance across various time horizons, showcasing both strengths and challenges when compared to its Pharma Fund peers and the Nifty Pharma TRI benchmark. This analysis examines the fund’s returns over periods ranging from one month to ten years, alongside its Systematic Investment Plan (SIP) performance, highlighting its rankings within the Pharma Fund category and its ability to outperform or underperform the benchmark and category averages.

  • The fund has given a return of -1.46%, -7.06 and -7.5 in last one, three and six months respectively. In the same period the category average return was -0.22%, -2.44% and -3.73% respectively.
  • Dsp Healthcare Fund has given a return of 2.15% in last one year. In the same period the Nifty Pharma TRI return was 12.8%. The fund has given 10.65% less return than the benchmark return.
  • The fund has given a return of 22.56% in last three years and rank 8th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 26.24%. The fund has given 3.68% less return than the benchmark return.
  • Dsp Healthcare Fund has given a return of 15.43% in last five years and category average returns is 16.72% in same period. The fund ranked 8.0th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 14.52%. The fund has given 0.91% more return than the benchmark return.
  • The fund has given a SIP return of -8.2% in last one year whereas category average SIP return is -0.7%. The fund one year return rank in the category is 14th in 14 funds
  • The fund has SIP return of 7.58% in last three years and ranks 7th in 7 funds. Mirae Asset Healthcare Fund has given the highest SIP return (15.98%) in the category in last three years.
  • The fund has SIP return of 13.14% in last five years whereas category average SIP return is 15.54%.

Dsp Healthcare Fund Risk Analysis

  • The fund has a standard deviation of 14.57 and semi deviation of 9.99. The category average standard deviation is 15.51 and semi deviation is 10.99.
  • The fund has a Value at Risk (VaR) of -17.66 and a maximum drawdown of -13.27. The category average VaR is -18.18 and the maximum drawdown is -14.76. The fund has a beta of 0.8 which shows that fund is less volatile than the benchmark.

Standard deviation measures the fund's return volatility and Semi deviation focuses on downside volatility. Value at Risk (VaR) is a measure of the risk of investments. Maximum Drawdown is the maximum loss from a peak to a trough of a portfolio. Beta measures the volatility of the fund compared to the benchmark. A beta of 1 indicates that the fund will move in line with the benchmark. A beta of more than 1 indicates that the fund will be more volatile than the benchmark and vice versa.


  • Very Good Performance in Pharma Fund Category
  • Good Performance in Pharma Fund Category
  • Poor Performance in Pharma Fund Category
  • Very Poor Performance in Pharma Fund Category

    • Investors beware: Mutual Fund investments are subject to market risks. Please read the scheme related documents carefully.

    Data Source: www.amfiindia.com

    SEBI Categorization


    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % -1.55 2.94
    -0.32
    		-2.34 | 2.41 14 | 16 Poor
    3M Return % -7.35 0.72
    -2.75
    		-7.35 | 0.84 16 | 16 Poor
    6M Return % -8.10 3.11
    -4.37
    		-8.10 | -0.41 16 | 16 Poor
    1Y Return % 0.81 12.80
    8.14
    		0.81 | 12.89 15 | 15 Poor
    3Y Return % 20.93 26.24
    24.40
    		20.93 | 27.56 8 | 8 Poor
    5Y Return % 13.87 14.52
    15.33
    		13.87 | 16.86 8 | 8 Poor
    7Y Return % 19.93 14.92
    19.60
    		18.52 | 20.87 3 | 7 Good
    1Y SIP Return % -9.43
    -2.09
    		-9.43 | 4.05 15 | 15 Poor
    3Y SIP Return % 6.06
    11.91
    		6.06 | 14.23 8 | 8 Poor
    5Y SIP Return % 11.57
    14.37
    		11.57 | 16.51 8 | 8 Poor
    7Y SIP Return % 16.49
    17.75
    		16.49 | 19.41 7 | 7 Poor
    Standard Deviation 14.57
    15.51
    		14.34 | 16.43 2 | 8 Very Good
    Semi Deviation 9.99
    10.99
    		9.99 | 11.68 1 | 8 Very Good
    Max Drawdown % -13.27
    -14.76
    		-16.36 | -12.33 2 | 8 Very Good
    VaR 1 Y % -17.66
    -18.18
    		-21.68 | -15.67 5 | 8 Average
    Average Drawdown % -3.66
    -5.42
    		-6.79 | -3.66 1 | 8 Very Good
    Sharpe Ratio 1.08
    1.19
    		1.08 | 1.37 8 | 8 Poor
    Sterling Ratio 0.96
    1.02
    		0.92 | 1.18 7 | 8 Poor
    Sortino Ratio 0.59
    0.63
    		0.56 | 0.72 7 | 8 Poor
    Jensen Alpha % 0.33
    1.56
    		-0.45 | 4.64 6 | 8 Average
    Treynor Ratio -0.47
    -0.42
    		-0.47 | -0.39 8 | 8 Poor
    Modigliani Square Measure % 24.56
    26.49
    		24.56 | 29.65 8 | 8 Poor
    Alpha % -2.78
    -1.30
    		-2.78 | 1.82 8 | 8 Poor
    Return data last Updated On : March 13, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : Feb. 27, 2026
    KPIs: Key Performance Indicators

    Rotate the phone! Best viewed in landscape mode on mobile.
    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % -1.46 2.94 -0.22 -2.22 | 2.53 14 | 16 Poor
    3M Return % -7.06 0.72 -2.44 -7.06 | 1.19 16 | 16 Poor
    6M Return % -7.50 3.11 -3.73 -7.50 | 0.40 16 | 16 Poor
    1Y Return % 2.15 12.80 9.60 2.15 | 14.22 15 | 15 Poor
    3Y Return % 22.56 26.24 25.86 22.56 | 28.62 8 | 8 Poor
    5Y Return % 15.43 14.52 16.72 15.43 | 17.98 8 | 8 Poor
    7Y Return % 21.69 14.92 21.05 19.72 | 22.39 3 | 7 Good
    1Y SIP Return % -8.20 -0.70 -8.20 | 5.57 14 | 14 Poor
    3Y SIP Return % 7.58 13.15 7.58 | 15.98 7 | 7 Poor
    5Y SIP Return % 13.14 15.54 13.14 | 17.53 7 | 7 Poor
    7Y SIP Return % 18.22 19.05 18.22 | 20.53 6 | 6 Average
    Standard Deviation 14.57 15.51 14.34 | 16.43 2 | 8 Very Good
    Semi Deviation 9.99 10.99 9.99 | 11.68 1 | 8 Very Good
    Max Drawdown % -13.27 -14.76 -16.36 | -12.33 2 | 8 Very Good
    VaR 1 Y % -17.66 -18.18 -21.68 | -15.67 5 | 8 Average
    Average Drawdown % -3.66 -5.42 -6.79 | -3.66 1 | 8 Very Good
    Sharpe Ratio 1.08 1.19 1.08 | 1.37 8 | 8 Poor
    Sterling Ratio 0.96 1.02 0.92 | 1.18 7 | 8 Poor
    Sortino Ratio 0.59 0.63 0.56 | 0.72 7 | 8 Poor
    Jensen Alpha % 0.33 1.56 -0.45 | 4.64 6 | 8 Average
    Treynor Ratio -0.47 -0.42 -0.47 | -0.39 8 | 8 Poor
    Modigliani Square Measure % 24.56 26.49 24.56 | 29.65 8 | 8 Poor
    Alpha % -2.78 -1.30 -2.78 | 1.82 8 | 8 Poor
    Return data last Updated On : March 13, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : Feb. 27, 2026
    KPIs: Key Performance Indicators

    Disclaimer: Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns for periods above 1 year are annualised.


    Date Dsp Healthcare Fund NAV Regular Growth Dsp Healthcare Fund NAV Direct Growth
    13-03-2026 36.455 40.584
    12-03-2026 36.919 41.099
    11-03-2026 37.183 41.392
    10-03-2026 37.184 41.392
    09-03-2026 37.081 41.276
    06-03-2026 37.038 41.223
    05-03-2026 37.398 41.623
    04-03-2026 37.119 41.311
    02-03-2026 37.814 42.081
    27-02-2026 38.105 42.4
    26-02-2026 38.221 42.528
    25-02-2026 37.888 42.156
    24-02-2026 37.349 41.554
    23-02-2026 37.351 41.556
    20-02-2026 37.075 41.244
    19-02-2026 37.236 41.421
    18-02-2026 37.613 41.84
    17-02-2026 37.272 41.458
    13-02-2026 37.03 41.184

    Fund Launch Date: 12/Nov/2018
    Fund Category: Pharma Fund
    Investment Objective: The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
    Fund Description: An open ended equity scheme investing in healthcare and pharmaceutical sector
    Fund Benchmark: S&P BSE HEALTHCARE (Total Return Index)
    Source: Fund FactSheet

    Disclaimer: NO INVESTMENT ADVICE. The Content is for informational purposes only.